RIPK1 activation mediates neuroinflammation and disease progression in multiple sclerosis.


Journal

Cell reports
ISSN: 2211-1247
Titre abrégé: Cell Rep
Pays: United States
ID NLM: 101573691

Informations de publication

Date de publication:
11 05 2021
Historique:
received: 03 07 2020
revised: 27 02 2021
accepted: 20 04 2021
entrez: 12 5 2021
pubmed: 13 5 2021
medline: 10 2 2022
Statut: ppublish

Résumé

Receptor interacting protein kinase 1 (RIPK1) mediates cell death and inflammatory signaling and is increased in multiple sclerosis (MS) brain samples. Here, we investigate the role of glial RIPK1 kinase activity in mediating MS pathogenesis. We demonstrate RIPK1 levels correlate with MS disease progression. We find microglia are susceptible to RIPK1-mediated cell death and identify an inflammatory gene signature that may contribute to the neuroinflammatory milieu in MS patients. We uncover a distinct role for RIPK1 in astrocytes in regulating inflammatory signaling in the absence of cell death and confirm RIPK1-kinase-dependent regulation in human glia. Using a murine MS model, we show RIPK1 inhibition attenuates disease progression and suppresses deleterious signaling in astrocytes and microglia. Our results suggest RIPK1 kinase activation in microglia and astrocytes induces a detrimental neuroinflammatory program that contributes to the neurodegenerative environment in progressive MS.

Identifiants

pubmed: 33979622
pii: S2211-1247(21)00446-0
doi: 10.1016/j.celrep.2021.109112
pmc: PMC8917516
mid: NIHMS1783515
pii:
doi:

Substances chimiques

Receptor-Interacting Protein Serine-Threonine Kinases EC 2.7.11.1
Ripk1 protein, mouse EC 2.7.11.1

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

109112

Subventions

Organisme : NIA NIH HHS
ID : R56 AG058642
Pays : United States
Organisme : NINDS NIH HHS
ID : R21 NS111395
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI144400
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI146855
Pays : United States
Organisme : NIAID NIH HHS
ID : R21 AI128547
Pays : United States

Informations de copyright

Copyright © 2021 The Author(s). Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests M.Z., F.P., L.W., C.Z., A.M., Y.R., M.L., R.G., L.G., P.L., T.X., T.H., and D.O. were employees of Sanofi at the time this research was conducted. The authors declare no other conflicts of interest.

Références

Cell Death Dis. 2018 Apr 27;9(5):500
pubmed: 29703889
J Neuroimmunol. 2014 Sep 15;274(1-2):53-61
pubmed: 25005117
Cell Rep. 2019 Aug 27;28(9):2275-2287.e5
pubmed: 31461645
Nat Commun. 2014 Apr 03;5:3551
pubmed: 24699451
Front Immunol. 2018 Feb 19;9:217
pubmed: 29515568
J Neuroimmunol. 2014 May 15;270(1-2):56-60
pubmed: 24657029
Exp Neurol. 2010 Nov;226(1):148-58
pubmed: 20736006
Genes Immun. 2010 Jul;11(5):397-405
pubmed: 20555355
Mol Cell. 2014 Apr 10;54(1):133-146
pubmed: 24703947
J Med Chem. 2018 Mar 22;61(6):2384-2409
pubmed: 29485864
J Neurol. 2021 Apr;268(4):1210-1221
pubmed: 31363847
Curr Treat Options Neurol. 2018 Apr 7;20(5):12
pubmed: 29627873
Cell Death Dis. 2020 Oct 23;11(10):904
pubmed: 33097690
Proc Natl Acad Sci U S A. 2018 Jan 9;115(2):E302-E309
pubmed: 29279367
J Neurosci. 2014 Sep 3;34(36):11929-47
pubmed: 25186741
Proc Natl Acad Sci U S A. 2019 Mar 19;116(12):5675-5680
pubmed: 30837313
J Mol Neurosci. 2014 Jul;53(3):500-5
pubmed: 24395091
Immunity. 2020 Feb 18;52(2):222-240
pubmed: 31924476
Neuron. 2018 Feb 21;97(4):742-768
pubmed: 29470968
J Immunol. 2008 Jun 1;180(11):7376-84
pubmed: 18490737
J Neurol. 2018 Nov;265(11):2540-2547
pubmed: 30167879
Acta Neuropathol. 2017 Jan;133(1):13-24
pubmed: 27988845
Cell. 2017 Apr 06;169(2):301-313.e11
pubmed: 28366204
Nature. 2017 Jan 26;541(7638):481-487
pubmed: 28099414
Front Immunol. 2017 May 18;8:531
pubmed: 28572801
Immunity. 2013 Sep 19;39(3):443-53
pubmed: 24012422
Cell. 2014 May 22;157(5):1189-202
pubmed: 24813850
Nat Neurosci. 2017 Oct;20(10):1371-1376
pubmed: 28846081
Mult Scler. 2017 Oct;23(12):1593-1599
pubmed: 29041864
Nat Immunol. 2000 Dec;1(6):489-95
pubmed: 11101870
Cell. 2008 May 16;133(4):693-703
pubmed: 18485876
Mol Genet Metab. 2018 Dec;125(4):345-350
pubmed: 30392741
Neuron. 2016 Jan 6;89(1):37-53
pubmed: 26687838
Cell. 2018 Sep 6;174(6):1477-1491.e19
pubmed: 30146158
Brain. 2017 Jul 1;140(7):1900-1913
pubmed: 28541408
Cell Death Dis. 2013 Jul 11;4:e716
pubmed: 23846218
Mult Scler Int. 2011;2011:767083
pubmed: 22096642
J Neuroimmunol. 2017 Dec 15;313:56-60
pubmed: 29153609
Front Immunol. 2019 Jan 10;9:3116
pubmed: 30687321
Nat Rev Neurosci. 2019 Jan;20(1):19-33
pubmed: 30467385
Nat Commun. 2017 Aug 25;8(1):359
pubmed: 28842570
Cold Spring Harb Perspect Med. 2019 Jan 2;9(1):
pubmed: 29358321
Mult Scler. 2018 Apr;24(4):432-439
pubmed: 29512406
AAPS J. 2016 May;18(3):545-9
pubmed: 26902301
Neurol Neuroimmunol Neuroinflamm. 2016 Jan 07;3(1):e191
pubmed: 26770997
Mult Scler Relat Disord. 2019 Nov;36:101384
pubmed: 31550559
Front Immunol. 2018 Jul 31;9:1753
pubmed: 30108586
Front Immunol. 2015 Oct 22;6:541
pubmed: 26557120
Trends Mol Med. 2019 Feb;25(2):112-123
pubmed: 30578090
Am J Pathol. 1999 Jan;154(1):45-51
pubmed: 9916917
Nature. 2019 Sep;573(7772):75-82
pubmed: 31316211
Nat Chem Biol. 2005 Jul;1(2):112-9
pubmed: 16408008
Mult Scler. 2019 Mar;25(3):344-351
pubmed: 29320952
J Vis Exp. 2014 Apr 15;(86):
pubmed: 24797125
Cell Rep. 2015 Mar 24;10(11):1836-49
pubmed: 25801023
J Neurol Sci. 2005 Jun 15;233(1-2):183-98
pubmed: 15896809
Immunity. 2010 Oct 29;33(4):607-19
pubmed: 20888269
J Autoimmun. 2015 Jan;56:45-55
pubmed: 25456971
J Immunol. 2011 Sep 1;187(5):2213-21
pubmed: 21788439
J Neuroimmunol. 2016 Feb 15;291:70-2
pubmed: 26857497
Glia. 2010 Mar;58(4):434-45
pubmed: 19780195
Cell Rep. 2020 Jan 21;30(3):699-713.e4
pubmed: 31968247
Science. 2016 Aug 5;353(6299):603-8
pubmed: 27493188
J Immunoassay Immunochem. 2019;40(4):378-385
pubmed: 31268406
Nat Chem Biol. 2008 May;4(5):313-21
pubmed: 18408713
Nat Commun. 2018 Dec 17;9(1):5337
pubmed: 30559390
Proc Natl Acad Sci U S A. 2017 Oct 10;114(41):E8788-E8797
pubmed: 28904096
J Med Chem. 2019 May 23;62(10):5096-5110
pubmed: 31013427
Immunity. 2016 Jul 19;45(1):46-59
pubmed: 27396959

Auteurs

Matija Zelic (M)

Sanofi, Neurological Diseases, 49 New York Ave., Framingham, MA 01701, USA.

Fabrizio Pontarelli (F)

Sanofi, Neurological Diseases, 49 New York Ave., Framingham, MA 01701, USA.

Lisa Woodworth (L)

Sanofi, Neurological Diseases, 49 New York Ave., Framingham, MA 01701, USA.

Cheng Zhu (C)

Sanofi, Translational Sciences, 49 New York Ave., Framingham, MA 01701, USA.

Amy Mahan (A)

Sanofi, Neurological Diseases, 49 New York Ave., Framingham, MA 01701, USA.

Yi Ren (Y)

Sanofi, Neurological Diseases, 49 New York Ave., Framingham, MA 01701, USA.

Michael LaMorte (M)

Sanofi, Neurological Diseases, 49 New York Ave., Framingham, MA 01701, USA.

Ross Gruber (R)

Sanofi, Neurological Diseases, 49 New York Ave., Framingham, MA 01701, USA.

Aislinn Keane (A)

Department of Cell, Molecular & Developmental Biology, Tufts University School of Medicine, Boston, MA 02111, USA.

Pequita Loring (P)

Sanofi, Translational Sciences, 49 New York Ave., Framingham, MA 01701, USA.

Lilu Guo (L)

Sanofi, Translational Sciences, 49 New York Ave., Framingham, MA 01701, USA.

Tai-He Xia (TH)

Sanofi, Translational Sciences, 49 New York Ave., Framingham, MA 01701, USA.

Boyao Zhang (B)

Program in Innate Immunity, Division of Infectious Diseases and Immunology, Department of Medicine, University of Massachusetts Medical School, Worcester, MA 01605, USA.

Pontus Orning (P)

Program in Innate Immunity, Division of Infectious Diseases and Immunology, Department of Medicine, University of Massachusetts Medical School, Worcester, MA 01605, USA; Centre of Molecular Inflammation Research, Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway.

Egil Lien (E)

Program in Innate Immunity, Division of Infectious Diseases and Immunology, Department of Medicine, University of Massachusetts Medical School, Worcester, MA 01605, USA; Centre of Molecular Inflammation Research, Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway.

Alexei Degterev (A)

Department of Cell, Molecular & Developmental Biology, Tufts University School of Medicine, Boston, MA 02111, USA.

Timothy Hammond (T)

Sanofi, Neurological Diseases, 49 New York Ave., Framingham, MA 01701, USA.

Dimitry Ofengeim (D)

Sanofi, Neurological Diseases, 49 New York Ave., Framingham, MA 01701, USA. Electronic address: dimitry.ofengeim@sanofi.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH